Which GLP-1 Is Right for You? Ozempic vs Wegovy vs Zepbound vs Mounjaro (2026)

If you’ve started researching GLP-1 medications, you’ve probably noticed there seem to be four different drugs — Ozempic, Wegovy, Zepbound, Mounjaro — and no one explains how they relate. Here’s the secret that makes the whole decision simpler: there are only two actual medicines. Everything else is branding, diagnosis, and cost.

The map: four names, two medicines

• Semaglutide (made by Novo Nordisk) is sold as two brands:
  • Ozempic — FDA-approved for type 2 diabetes.
  • Wegovy — FDA-approved for chronic weight management.
• Tirzepatide (made by Eli Lilly) is also sold as two brands:
  • Mounjaro — FDA-approved for type 2 diabetes.
  • Zepbound — FDA-approved for chronic weight management.

So Ozempic and Wegovy are, at their core, the same molecule; Mounjaro and Zepbound are the same molecule. The difference between the pairs is what the FDA approved them for — and that, plus your insurance, usually decides which one you actually end up on.

One mechanism note that matters: semaglutide activates a single gut-hormone receptor (GLP-1), while tirzepatide activates two (GIP and GLP-1). That dual action is the leading theory for why tirzepatide edges ahead on average weight loss.

If your goal is weight loss, the shortlist is two

Wegovy and Zepbound are the two FDA-approved for weight management, so for most people choosing purely for weight loss, the real question is Wegovy vs Zepbound — which we break down in detail in Zepbound vs Wegovy. Ozempic and Mounjaro contain the same molecules but are approved for diabetes; you’ll hear about off-label use for weight, but whether that’s appropriate is squarely a decision for your prescriber, not a website.

Beyond the approved label, both weight-management drugs have picked up additional FDA-approved uses that may matter to you: Wegovy is also approved to reduce the risk of serious cardiovascular events in adults with established heart disease and obesity/overweight, and Zepbound became the first drug ever approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity (FDA, 2024). If either applies to you, it’s worth raising.

Results: what the head-to-head actually showed

For years, comparisons relied on separate trials. The SURMOUNT-5 head-to-head finally measured them directly: over 72 weeks, tirzepatide produced about 20% average body-weight loss versus about 14% for semaglutide (Aronne et al., NEJM 2025).

Three honest footnotes before you conclude “Zepbound wins for everyone”:

1. Averages hide the spread. On both drugs, some people lose far more than the mean and some far less. Your individual response can’t be predicted in advance.
2. The “second place” result is still extraordinary. Fourteen percent average loss was unthinkable from a medication a few years ago.
3. The best drug is the one you can get and stay on. Coverage, supply, tolerability, and price decide real-world outcomes as often as the pharmacology does.

Both share the same core gastrointestinal side effects — nausea, constipation, diarrhea, mostly early and around dose increases. Our side-effect survival guide applies to either, and the serious risks (pancreatitis, gallbladder disease, the thyroid-tumor boxed warning based on rodent data) apply to the whole class and belong in a conversation with your prescriber — not a feature you shop on.

Cost and access in 2026 — usually the real decider

At full list price, all four run above $1,000 per month without insurance (Novo Nordisk list-price disclosure). Almost nobody pays that if they look at the alternatives:

• Insurance first. If your plan covers a GLP-1 for your diagnosis, that’s usually the cheapest path by far. A provider who works your insurance — see our coverage guide — is worth it.
• Manufacturer self-pay programs (FDA-approved medication, below list).
  • Wegovy self-pay through NovoCare Pharmacy — recently around $349/month for standard pen doses (with lower intro pricing on early fills). Confirm the current figure, because Novo has changed it more than once.
  • Zepbound single-dose vials through LillyDirect — cash pricing that has run roughly $299–$449/month depending on dose and refill timing. Again, verify the live number before you commit.
• Compounded semaglutide/tirzepatide was the cheap route, but the FDA shortage that made large-scale compounding legal has been resolved, so that window is closing. Compounded GLP-1s are not FDA-approved products — understand the current legal picture in Is compounded semaglutide safe and legal in 2026? before choosing it.

We keep a full, updated breakdown of every route in the real cost of GLP-1s in 2026.

How to actually decide

Skip the “which is strongest” rabbit hole and answer these in order:

1. What does my insurance cover for my diagnosis? This eliminates most of the choice for most people. Start here.
2. Is there a clinical reason to prefer one? Heart disease, sleep apnea, diabetes, your history, other medications — your prescriber weighs these.
3. Which can I actually get and afford this month? Supply and self-pay pricing move; check both makers’ programs the same week you decide.
4. What’s the plan if it plateaus or I can’t tolerate it? People switch between these in both directions. Knowing the fallback beats agonizing over the first pick.

That conversation with a prescriber beats any internet comparison — including this one. If you don’t have a prescriber yet, our guide to getting a GLP-1 prescription online walks through the telehealth route, and our provider comparison ranks the major options on cost, medication type, and trust — with our paid partners deliberately not placed at the top.

Educational content, not medical advice. GLP-1 medications are prescription drugs with real risks and contraindications; only a licensed clinician who knows your history can tell you whether one is right for you, which one, and at what dose. Drug names, approvals, and prices change — verify current details with the manufacturer and your prescriber.